DESCRIPTION

A 46-year-old man was transferred from an outside hospital for evaluation of acute renal failure and non-ST-segment elevation myocardial infarction. During his initial presentation at the outside hospital, the patient was profoundly hypotensive with signs of respiratory failure. Owing to the perceived urgency, he was started on norepinephrine for hemodynamic support through a peripheral intravenous line. Following the resolution of hemodynamic instability, the patient was noted to have a large subcutaneous lesion on his right forearm around his peripheral intravenous site. The lesion consisted of a large serous bullae and exhibited marked pallor, coldness and mottling of the skin. The patient underwent mechanical debridement of the necrotic tissue and was treated with topical silver sulfadiazine.

Norepinephrine is an α-adrenergic agonist commonly used for the treatment of shock. A well-known side effect of norepinephrine is the potential for subcutaneous tissue ischemia through marked vasoconstriction and increased vascular permeability (figure 1). Cases of skin necrosis with peripheral infusions continue to be seen despite longstanding awareness that vasopressors need to be administered through a central venous catheter for rapid dilution. Treatment of extravasation injuries includes prompt discontinuation of the peripheral intravenous infusion, and the administration of a pharmacological vasodilator such as phentolamine, an α-adrenergic antagonist. Should subcutaneous necrosis occur, general wound care measures such as mechanical debridement are recommended.

Learning points

▸ Skin necrosis with subcutaneous extravasation of vasopressors continues to occur despite widespread knowledge of need to avoid peripheral venous administration.
▸ The pathophysiology involves the relatively high concentration of norepinephrine in both the recipient vein and adjacent blood vessels leading to vasoconstriction and increased vascular permeability.
▸ Treatment following the extravasation includes discontinuation of the intravenous site, pharmacological vasodilators and wound care.

Competing interests None.
Patient consent Obtained.

REFERENCES
